Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Purchases $24,840.24 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 996 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $24.94 per share, with a total value of $24,840.24. Following the acquisition, the insider directly owned 6,376,968 shares in the company, valued at approximately $159,041,581.92. This trade represents a 0.02% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 19th, Ra Capital Management, L.P. acquired 3,802 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.97 per share, with a total value of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.90 per share, with a total value of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.46 per share, with a total value of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Down 1.6%

Shares of Hemab Therapeutics stock opened at $25.89 on Friday. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.